Dr. Anthony Letai led a study showing an oral targeted drug that found encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML).
Drs. Richard Stone, Jeff Golden, and Robert Soiffer collaborated on a study using Rapid Heme Panel, a high-tech genetic test that provides critical information for treating blood cancer patients.
Former Dana-Farber/Boston Children’s Cancer and Blood Disorders Center patient Kate Franklin spent the summer interning in the lab of Dr. Loren Walensky, who treated her for leukemia when she was a child.
Tags: Leukemia, CopingWithCancer
Tags: ChildhoodCancer, RadioTelethon, Leukemia
Tags: MultipleMyeloma, Leukemia
Tags: BasicResearch, Leukemia, Lymphoma
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: